NuCana's twist on chemo drug Gemzar fails in phase 3 again

NuCana’s retooled chemotherapy candidate Acelarin has come up short in phase 3 again. The latest failure wipes out hopes that NuCana’s attempt to improve on gemcitabine, sold by Eli Lilly as Gemzar, will drive improved outcomes in biliary cancer.